Search clinical trials for: ABT-384

Total 5119 results

AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie (prior sponsor, Abbott)

Completed

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

Advanced Solid Tumors

Australia
Stragen France

Completed

First-In-Human PainCart Study for STR-324

Pain

Netherlands
AbbVie

Active, not recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Hepatitis C Virus (HCV)

United States, Australia, Austria, Canada, France, Germany, Italy, Spain
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers

Type2 Diabetes Mellitus
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
Linnaeus University
Kronoberg County Council; Capio Group

Completed

PCBH With the Addition of Self-help CBT

Quality of Life | Stress | Insomnia | Psychological Distress | Depression, Anxiety | Activities, Daily Living

Sweden
MedImmune LLC
AstraZeneca; MedImmune Ltd

Completed

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

Healthy

United States
University of California, San Francisco
National Institute of Mental Health (NIMH)

Completed

An Adaptive Intervention for Depression Among Latinos Living With HIV (Latino-SMART)

Depression

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Healthy Volunteers

United States
AbbVie (prior sponsor, Abbott)

Terminated

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Poland, Russian Federation, South Africa, Ukraine, United Kingdom
AbbVie

Terminated

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Schizophrenia

United States, Russian Federation, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
AbbVie

Terminated

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
AbbVie

Completed

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Relative Bioavailability

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Hepatitis C Virus Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Hepatitis C Virus Infection | Chronic Hepatitis C | Compensated Cirrhosis
Global Alliance for TB Drug Development

Terminated

A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers

Hypertension | Dyslipidemias

Korea, Republic of
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
AbbVie

Completed

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Solid Tumor
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)

Completed

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

A Safety and Tolerability Study of ABT-126 in Elderly

Alzheimer's Disease

United States
Abbott

Completed

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

Hepatitis C

United States
US Department of Veterans Affairs

Completed

Behavioral Treatments for Chronic Pain

Intractable Pain

United States
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
Kafrelsheikh University

Completed

Ridge Augmentation With Simultaneous Implant Placement Using Bone Blocks With Autogenous Tooth Graft

Implant | Ridge Augmentation | Autogenous Tooth Graft

Egypt
AbbVie

Completed

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection
AbbVie

No longer available

Expanded Access to ABT-414

Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
M.D. Anderson Cancer Center

Completed

Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Hematological Malignancies

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

United States, Canada, Singapore, Taiwan
Abbott

Terminated

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain

Healthy Volunteers

Canada
Abbott

Completed

A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans

Healthy

United States
Abbott

Completed

A Study of ABT-751 in Patients With Colorectal Cancer

Colorectal Cancer

United States
Abbott

Completed

A Study of ABT-751 in Patients With Renal Cell Cancer

Renal Cell Cancer

Canada, United States
AbbVie

Recruiting

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel
Boehringer Ingelheim

Completed

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
VA Office of Research and Development

Recruiting

Treatments for Insomnia in Veterans With PTSD

PTSD | Insomnia

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Schizophrenia

United States, Russian Federation, United Kingdom
AbbVie

Terminated

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

Mild Cognitive Impairment | Alzheimer's Disease

United States
AbbVie

Completed

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Schizophrenia

3

Subscribe